Antibody ID	ANTI0JCOZG
Antibody Name	Hrs9
Synonyms	Hrs9    Click to Show/Hide
Antigen Name	Tumor-associated calcium signal transducer 2 (TACSTD2)					Antigen Info
Click to Show/Hide the Sequence Information of This Antibody

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	-20.85%	Positive Trop2 expression (Trop2+++/++)
Method Description	In the Capan-1 xenograft model, the ADCs were administered at 5 mg/kg (qwk × 3, IV).
In Vivo Model	Capan-1 xenograft model
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	-20.85%	Positive Trop2 expression (Trop2+++/++)
Method Description	In the Capan-1 xenograft model, the ADCs were administered at 5 mg/kg (qwk × 3, IV).
In Vivo Model	Capan-1 xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	86.48%	Positive Trop2 expression (Trop2+++/++)
Method Description	In the MX-1 xenograft model, the ADCs were administered at 2.5 mg/kg (once, IV).
In Vivo Model	MX-1 xenograft model
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	86.48%	Positive Trop2 expression (Trop2+++/++)
Method Description	In the MX-1 xenograft model, the ADCs were administered at 2.5 mg/kg (once, IV).
In Vivo Model	MX-1 xenograft model
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	109.48%	Positive Trop2 expression (Trop2+++/++)
Method Description	In the MX-1 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
In Vivo Model	MX-1 xenograft model
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	109.48%	Positive Trop2 expression (Trop2+++/++)
Method Description	In the MX-1 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
In Vivo Model	MX-1 xenograft model
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	114.40%	Positive Trop2 expression (Trop2+++/++)
Method Description	In the Capan-1 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
In Vivo Model	Capan-1 xenograft model
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	114.40%	Positive Trop2 expression (Trop2+++/++)
Method Description	In the Capan-1 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
In Vivo Model	Capan-1 xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	157.8 ng/mL	Positive Trop2 expression (Trop2+++/++)
Method Description	MDA-MB-468 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC4 for 120 h.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	233 ng/mL	Positive Trop2 expression (Trop2+++/++)
Method Description	MX-1 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC4 for 120 h.
In Vitro Model	Breast carcinoma	MX-1 cells		CVCL_4774
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	640 ng/mL	Positive Trop2 expression (Trop2+++/++)
Method Description	MDA-MB-453 were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC4 for 120 h.
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 15000 ng/mL	Negative Trop2 expression (Trop2-)
Method Description	HGC27 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC4 for 120 h.
In Vitro Model	Gastric carcinoma	HGC27 cells		CVCL_1279

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	91.30%	Positive Trop2 expression (Trop2+++/++)
Method Description	In the MX-1 xenograft model, the ADCs were administered at 2.5 mg/kg (once, IV).
In Vivo Model	MX-1 xenograft model
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	91.30%	Positive Trop2 expression (Trop2+++/++)
Method Description	In the MX-1 xenograft model, the ADCs were administered at 2.5 mg/kg (once, IV).
In Vivo Model	MX-1 xenograft model
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	101.70%	Positive Trop2 expression (Trop2+++/++)
Method Description	In the Capan-1 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
In Vivo Model	Capan-1 xenograft model
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	101.70%	Positive Trop2 expression (Trop2+++/++)
Method Description	In the Capan-1 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
In Vivo Model	Capan-1 xenograft model
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	108.84%	Positive Trop2 expression (Trop2+++/++)
Method Description	In the MX-1 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
In Vivo Model	MX-1 xenograft model
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	108.84%	Positive Trop2 expression (Trop2+++/++)
Method Description	In the MX-1 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
In Vivo Model	MX-1 xenograft model

Ref 1	Drug conjugates and uses thereof